Glucosamine for Joint Pain: What the Trials Found

Table of Contents

1. The Short Answer
2. The Theory: Cartilage Is Made From Glucosamine
3. What Happens to a Swallowed Dose
4. The Encouraging Early Trials
5. The Large Independent Trials
6. The Key Trials at a Glance
7. Pooling the Evidence: Why Reviews Disagree
8. What the Arthritis Guidelines Say
9. A Caution for Diabetes and High Blood Sugar
10. Where the Evidence Points, and What the Guidelines Favor
11. Key Research Papers
12. Connections
13. Featured Videos

The Short Answer

For most people with knee or hip osteoarthritis, glucosamine does not reduce pain by an amount a person would notice, compared with a placebo pill. That is the conclusion of the largest trial ever run on it (the US government-funded GAIT study of 1,583 patients), of its two-year extension, of an Australian two-year trial of 605 people, of a Spanish six-month trial, and of a network meta-analysis that pooled the ten largest trials. The 2019 guideline from the American College of Rheumatology recommends strongly against it, and the 2019 guideline from the Osteoarthritis Research Society International (OARSI) also recommends against all glucosamine formulations.

The picture is not completely one-sided, and this page says so where it isn't. One patented pharmaceutical form of glucosamine sulfate produced positive results in a series of trials, a European society (ESCEO) still recommends that form, and one recent meta-analysis found a "marginally favorable" effect on pain. Why the results split this way — along lines of formulation, trial quality and funding — is the most useful thing to understand about glucosamine, and it is explained below.

Back to Table of Contents

The Theory: Cartilage Is Made From Glucosamine

Joint cartilage is a tough, slippery cushion that covers the ends of bones. Much of its bulk is water held in place by long sugar chains called glycosaminoglycans — chondroitin sulfate, keratan sulfate and hyaluronan among them. These chains are built from repeating pairs of sugars, and one member of each pair is an amino sugar: glucosamine or its close relative galactosamine. In osteoarthritis the cartilage thins and the joint space on an X-ray narrows.

The supplement theory follows directly: if cartilage is built from glucosamine, extra glucosamine should give the cartilage cells more raw material, slow the thinning, and perhaps ease pain. It is an appealing idea, and it has two weak points.

• The body already makes its own. Every cell can build glucosamine from glucose and the amino acid glutamine, using energy from ATP, through a route called the hexosamine pathway. Cartilage cells are not known to be starved of it. The full story is on How the Body Makes Glucosamine.
• Very little of a swallowed dose reaches the joint as glucosamine. Laboratory experiments showing glucosamine protecting cartilage cells mostly used concentrations far higher than anything measured in human blood after a normal dose. The next section gives the numbers.

Back to Table of Contents

What Happens to a Swallowed Dose

The usual dose in trials is 1,500 mg of glucosamine a day. Several groups have measured what that does to blood levels.

• Biggee and colleagues, 2006 (independent). Eighteen people with osteoarthritis took 1,500 mg of glucosamine sulfate after an overnight fast. Before the dose, glucosamine was below the test's detection limit in everyone. Afterwards it peaked at between 1.9 and 11.5 micromoles per litre. The authors pointed out that laboratory studies claiming effects on cartilage generally used concentrations "well in excess of 100 micromol/l", and that the highest level they measured had previously been shown to contribute less than 2% of the building blocks cultured human cartilage cells put into chondroitin sulfate. Their conclusion: this "raises questions about current biological rationales for glucosamine use."
• Persiani and colleagues, 2005. In 12 healthy volunteers given a patented crystalline glucosamine sulfate, the 1,500 mg daily dose raised plasma glucosamine more than 30-fold from baseline, peaking at about 10 micromoles per litre. Tripling the dose to 3,000 mg did not raise levels in proportion. The body's own background glucosamine was measurable before any dose was given.
• Persiani and colleagues, 2007. In 12 people with osteoarthritis taking the same product for 14 days, the median level three hours after a dose was 7.17 micromoles per litre in blood and 4.34 micromoles per litre in the fluid inside the knee joint.
• Setnikar and Rovati, 2001, a review of absorption studies, estimated that at least 88.7% of an oral dose is absorbed from the gut, but that absolute oral bioavailability was 44%, the difference probably being consumed by the liver on its first pass.

The two Persiani studies and the Setnikar review were written by researchers based at the research laboratory of the company that makes the crystalline sulfate form, and they concluded that the measured levels were "in line with those found to be effective in selected in vitro mechanistic studies." The independent group (Biggee) read similar numbers — roughly 10 micromoles per litre at the peak — the opposite way. Both readings are reported here; the plain fact both agree on is that a standard dose gives blood and joint levels in the low single or double digits of micromoles per litre, far below the 100-plus used in many laboratory experiments.

Back to Table of Contents

The Encouraging Early Trials

The trial that did most to launch glucosamine's reputation as a possible "disease-modifying" treatment was published in The Lancet in 2001 by Reginster and colleagues in Belgium.

• Design: 212 people with knee osteoarthritis were randomly assigned to 1,500 mg of glucosamine sulfate once daily or a placebo for 3 years. Knee X-rays were taken at the start, after 1 year and after 3 years.
• Joint space: the 106 patients on placebo lost an average of 0.31 mm of joint space over 3 years. The 106 on glucosamine sulfate lost 0.06 mm, which was not a significant loss.
• Symptoms: on the standard WOMAC questionnaire, symptoms "worsened slightly" in the placebo group while the glucosamine group improved.
• Safety: no difference in side effects or withdrawals.

The authors concluded that glucosamine sulfate "could be a disease modifying agent in osteoarthritis." The Cochrane review described below found that two three-year trials of this preparation, taken together, showed slower narrowing of the knee joint space on X-ray.

A neutral note on who ran these studies: the positive long-term trials and the pharmacokinetic work above all used one patented crystalline glucosamine sulfate product. The pharmacokinetic papers list the manufacturer's own research laboratory as the authors' affiliation, and one of their authors is also a co-author of the 2001 Lancet trial. Industry funding does not make a result wrong, but it is one of the factors reviewers have tested, and as the meta-analysis section shows, commercially funded trials reported larger benefits than independent ones.

Back to Table of Contents

The Large Independent Trials

From 2006 onward, a series of large, double-blind trials run by university groups and public research networks tested glucosamine head-to-head with placebo.

GAIT: the US government trial (Clegg 2006)

The Glucosamine/chondroitin Arthritis Intervention Trial enrolled 1,583 people with painful knee osteoarthritis and randomly assigned them to glucosamine 1,500 mg daily, chondroitin sulfate 1,200 mg daily, both together, the anti-inflammatory drug celecoxib, or placebo for 24 weeks. Success was defined as at least a 20% drop in knee pain.

• 60.1% of the placebo group reached that goal — a reminder of how much joint pain improves on a dummy pill.
• Glucosamine did 3.9 percentage points better than placebo, which was not statistically significant (P=0.30). The combination did 6.5 points better (P=0.09), also not significant.
• Celecoxib, the active control, did 10.0 points better (P=0.008) — showing the trial was capable of detecting a real effect.
• In a smaller group with moderate-to-severe pain, the combination did better than placebo (79.2% vs 54.3%). The authors labelled this an exploratory finding that needed confirmation.

GAIT at two years (Sawitzke 2010)

A subset of 662 GAIT patients continued their assigned treatment for 24 months. Compared with placebo, the odds of a 20% pain reduction were 1.16 for glucosamine and 1.21 for celecoxib, neither statistically significant. The authors' conclusion: "Over 2 years, no treatment achieved a clinically important difference in WOMAC pain or function as compared with placebo," though glucosamine and celecoxib showed non-significant trends in a favourable direction.

LEGS: the Australian two-year trial (Fransen 2015)

605 people aged 45 to 75 with chronic knee pain were randomly assigned to glucosamine sulfate 1,500 mg, chondroitin sulfate 800 mg, both, or placebo, once daily for 2 years.

• Pain: all four groups reported less knee pain over the first year, with no significant difference between them (p=0.93). Glucosamine alone did no better than placebo.
• Joint space: glucosamine alone showed no structural effect. The glucosamine-plus-chondroitin combination slowed joint-space narrowing by 0.10 mm over 2 years, a result that only just reached statistical significance (p=0.046).

The Spanish combination trial (Roman-Blas 2017)

164 people with knee osteoarthritis and moderate-to-severe pain took either chondroitin sulfate 1,200 mg plus glucosamine sulfate 1,500 mg, or placebo, once daily for 6 months. In the main analysis the combination did worse than placebo: pain fell 19% on the combination and 33% on placebo. Among patients who completed the study as planned there was no difference. The title states the conclusion: the combination "Shows No Superiority Over Placebo."

MOVES: compared with a painkiller, not a placebo (Hochberg 2016)

This European trial gave 606 people with painful knee osteoarthritis either chondroitin sulfate plus glucosamine hydrochloride three times a day or celecoxib 200 mg daily for 6 months. Pain fell by about half in both groups (50.1% and 50.2%), and the combination met the pre-set test of being "non-inferior" to celecoxib. The trial had no placebo group, so it cannot say how much of either group's improvement a dummy pill would also have produced — in GAIT, celecoxib beat placebo by 10 percentage points, and in the Spanish trial placebo alone cut pain by a third.

Back to Table of Contents

The Key Trials at a Glance

Back to Table of Contents

Pooling the Evidence: Why Reviews Disagree

Meta-analyses combine many trials to get a clearer answer. On glucosamine, the way they split is itself the finding.

Cochrane review (Towheed 2005)

This review pooled 20 randomized trials with 2,570 patients. Taken all together, glucosamine looked better than placebo for pain. But the review then divided the trials two ways:

• By trial quality: the eight trials with adequate allocation concealment — the safeguard that stops researchers from knowing or influencing who gets the real pill — "failed to show benefit of glucosamine for pain and WOMAC function."
• By formulation: the ten trials of one patented pharmaceutical preparation found a large effect on pain, while the trials of other glucosamine preparations found no statistically significant benefit for pain or function.
• On the WOMAC questionnaire, glucosamine did not beat placebo for either type of preparation. Glucosamine was as safe as placebo.

Network meta-analysis (Wandel 2010, BMJ)

This Swiss analysis included only large trials (more than 200 patients each) — 10 trials with 3,803 patients. On a 10 cm pain scale, glucosamine reduced pain by 0.4 cm more than placebo. The researchers had decided in advance that a difference smaller than 0.9 cm would not be noticeable to patients, and none of the estimates came close to that line. Changes in joint space were "all minute." Crucially, industry-independent trials showed smaller effects than commercially funded trials (P=0.02). The authors concluded that glucosamine, chondroitin and their combination "do not reduce joint pain or have an impact on narrowing of joint space."

A more favourable review (Ogata 2018)

A Japanese review of 18 trial reports from 2003 to 2016 found "a marginally favorable effect of glucosamine on VAS pain scores," while the effect on knee function measured by WOMAC was "small and not significant." The authors concluded that glucosamine "has the potential to alleviate knee OA pain" and that more research was needed. It is fair to report this review; it is also fair to note that "marginal" benefit on one scale and no significant benefit on the other is consistent with the larger analyses above.

Putting it together

Three patterns repeat across the reviews: the better-concealed trials show less benefit, independently funded trials show less benefit than commercially funded ones, and the positive results cluster around one pharmaceutical product. When the strongest, largest and most independent trials are taken on their own, the benefit shrinks to a size patients would not notice.

Back to Table of Contents

What the Arthritis Guidelines Say

• American College of Rheumatology / Arthritis Foundation, 2019 (Kolasinski). The guideline strongly recommends against glucosamine for knee, hip and hand osteoarthritis. Its strong recommendations for treatment were exercise, weight loss for people with knee or hip osteoarthritis who are overweight, self-management programmes, tai chi, a cane, bracing, topical anti-inflammatory gels for the knee, oral anti-inflammatory drugs and steroid injections into the knee.
• OARSI, 2019 (Bannuru). The core treatments for knee osteoarthritis are arthritis education and structured land-based exercise, with or without dietary weight management. According to a comparison written jointly by members of both guideline groups (Arden 2021), OARSI "strongly recommends against" glucosamine and chondroitin, "including all glucosamine and chondroitin formulations."
• ESCEO, 2019, as described by Arden 2021. The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases takes a different view: it recommends pharmaceutical-grade glucosamine and chondroitin sulfate. The comparison paper notes that, despite this difference, the two guidelines agree on most recommendations — both put education, structured exercise and weight loss at the core.

The disagreement between OARSI and ESCEO mirrors the split in the trial evidence: ESCEO gives weight to the pharmaceutical-grade product's trial record; OARSI and the ACR weigh the large independent trials and pooled analyses more heavily. Both guideline groups agree that exercise and weight management come first.

Back to Table of Contents

A Caution for Diabetes and High Blood Sugar

Glucosamine enters the same chemical pathway the body uses to sense glucose, and it enters past the pathway's main control point. In cell and animal studies, extra glucosamine flowing down that pathway causes insulin resistance. Human studies are mixed, but two are directly relevant to people who might take it for their joints:

• Pham 2007: 38 volunteers without known blood-sugar problems took 1,500 mg of glucosamine daily for 6 weeks. Their insulin-resistance score (HOMA-IR) rose from 2.8 to 3.2. The authors concluded that people with poorer insulin sensitivity are at risk of worsening insulin resistance at the doses used for osteoarthritis.
• Biggee 2007: in 16 people with osteoarthritis given a glucose drink with or without 1,500 mg of glucosamine sulfate, the three who turned out to have previously undiagnosed abnormal glucose tolerance showed significantly higher glucose levels after glucosamine.

Other short trials found no worsening of insulin sensitivity or HbA1c, and some large observational studies even linked glucosamine use to lower diabetes risk; those findings, and why they don't settle the question, are covered on Glucosamine, Blood Sugar and Diabetes. Taken together, the research raises a concern for people with diabetes, prediabetes, high fasting glucose or an elevated HbA1c: a plausible risk, not a proven harm, with no meaningful joint benefit shown to set against it. For people already taking it — especially alongside diabetes medicines or the blood thinner warfarin — any change, and checks of blood glucose and HbA1c, are questions worth raising with a clinician. Other safety issues are on Glucosamine Safety.

Back to Table of Contents

Where the Evidence Points, and What the Guidelines Favor

The research does not support glucosamine supplements for joint pain. The largest and most independent trials found little or no benefit over placebo, the pooled analyses put the average effect below what a patient would notice, and two of the three major 2019 guidelines recommend against it. The positive results that exist are concentrated in one pharmaceutical product, in trials partly funded by its maker, and in trials with weaker safeguards against bias. This is a summary of the published evidence, not personal medical advice; decisions about medicines and supplements belong with a clinician.

What the guidelines agree on

• Exercise. Structured, land-based exercise is a core treatment in both the ACR and OARSI guidelines. Strengthening the muscles around the knee and hip takes load off the joint. Gentle options such as tai chi were strongly recommended by the ACR.
• Weight. For people with knee or hip osteoarthritis who carry extra weight, losing some of it is a strong ACR recommendation and part of OARSI's core care for the knee. See Exercise for Weight Loss.
• Education and self-management — learning how the condition behaves and pacing activity.

The full picture of the disease is on the Osteoarthritis page.

Further reading on this site

The pages below look at other joint-support approaches. The evidence behind each is different in size and quality, none is a proven cure for osteoarthritis, and each page sets out its own studies so readers can judge them:

• Boswellia for Joints and Osteoarthritis
• Collagen and Joint Health
• Sulfur and Joint Health
• Turmeric: Anti-Inflammatory and Joint Health

And for a related question — whether the body is better served by the raw materials it uses to make its own glucosamine — see Glutamine Instead of Glucosamine?

Back to Table of Contents

Key Research Papers

1. Biggee BA, Blinn CM, McAlindon TE, et al. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Annals of the Rheumatic Diseases. 2006;65(2):222-226. — doi:10.1136/ard.2005.036368 (PubMed PMID: 16079170)
2. Persiani S, Roda E, Rovati LC, et al. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis and Cartilage. 2005;13(12):1041-1049. — doi:10.1016/j.joca.2005.07.009 (PubMed PMID: 16168682)
3. Persiani S, Rotini R, Trisolino G, et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis and Cartilage. 2007;15(7):764-772. — doi:10.1016/j.joca.2007.01.019 (PubMed PMID: 17353133)
4. Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung. 2001;51(9):699-725. — doi:10.1055/s-0031-1300105 (PubMed PMID: 11642003)
5. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251-256. — doi:10.1016/S0140-6736(00)03610-2 (PubMed PMID: 11214126)
6. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine. 2006;354(8):795-808. — doi:10.1056/NEJMoa052771 (PubMed PMID: 16495392)
7. Sawitzke AD, Shi H, Finco MF, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Annals of the Rheumatic Diseases. 2010;69(8):1459-1464. — doi:10.1136/ard.2009.120469 (PubMed PMID: 20525840)
8. Fransen M, Agaliotis M, Nairn L, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Annals of the Rheumatic Diseases. 2015;74(5):851-858. — doi:10.1136/annrheumdis-2013-203954 (PubMed PMID: 24395557)
9. Hochberg MC, Martel-Pelletier J, Monfort J, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Annals of the Rheumatic Diseases. 2016;75(1):37-44. — doi:10.1136/annrheumdis-2014-206792 (PubMed PMID: 25589511)
10. Roman-Blas JA, Castañeda S, Sánchez-Pernaute O, et al. Combined treatment with chondroitin sulfate and glucosamine sulfate shows no superiority over placebo for reduction of joint pain and functional impairment in patients with knee osteoarthritis: a six-month multicenter, randomized, double-blind, placebo-controlled clinical trial. Arthritis & Rheumatology. 2017;69(1):77-85. — doi:10.1002/art.39819 (PubMed PMID: 27477804)
11. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database of Systematic Reviews. 2005;2005(2):CD002946. — doi:10.1002/14651858.CD002946.pub2 (PubMed PMID: 15846645)
12. Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675. — doi:10.1136/bmj.c4675 (PubMed PMID: 20847017)
13. Ogata T, Ideno Y, Akai M, et al. Effects of glucosamine in patients with osteoarthritis of the knee: a systematic review and meta-analysis. Clinical Rheumatology. 2018;37(9):2479-2487. — doi:10.1007/s10067-018-4106-2 (PubMed PMID: 29713967)
14. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis & Rheumatology. 2020;72(2):220-233. — doi:10.1002/art.41142 (PubMed PMID: 31908163)
15. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage. 2019;27(11):1578-1589. — doi:10.1016/j.joca.2019.06.011 (PubMed PMID: 31278997)
16. Arden NK, Perry TA, Bannuru RR, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nature Reviews Rheumatology. 2021;17(1):59-66. — doi:10.1038/s41584-020-00523-9 (PubMed PMID: 33116279)
17. Pham T, Cornea A, Blick KE, et al. Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance. American Journal of the Medical Sciences. 2007;333(6):333-339. — doi:10.1097/MAJ.0b013e318065bdbe (PubMed PMID: 17570985)
18. Biggee BA, Blinn CM, Nuite M, et al. Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis. Annals of the Rheumatic Diseases. 2007;66(2):260-262. — doi:10.1136/ard.2006.058222 (PubMed PMID: 16818461)

PubMed Topic Searches

1. PubMed: Glucosamine knee osteoarthritis randomized trials
2. PubMed: Glucosamine and chondroitin meta-analyses
3. PubMed: Glucosamine blood and joint-fluid levels
4. PubMed: Osteoarthritis guidelines on glucosamine

This content is provided for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning or stopping any supplement.

Back to Table of Contents

Connections

• All Amino Acids
• Glucosamine
• How the Body Makes Glucosamine
• Glucosamine, Blood Sugar and Diabetes
• Glutamine Instead of Glucosamine?
• History of Glucosamine
• Glucosamine Safety
• Osteoarthritis
• Arthritis
• Collagen
• Collagen and Joint Health
• Sulfur and Joint Health
• Boswellia for Osteoarthritis
• Turmeric and Joint Health
• Bone Broth
• Glutamine
• Magnesium
• Tai Chi
• Type 2 Diabetes
• Hemoglobin A1C (Lab Test)

Back to Table of Contents

Featured Videos